Trial Profile
Safety and efficacy of exenatide as monotherapy in drug naive patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Amylin Pharmaceuticals
- 30 Oct 2009 According to a Amylin media release, Byetta has been approved by the US FDA as first-line treatment for type 2 diabetes mellitus.
- 09 Jan 2008 Status changed from in progress to completed.
- 06 Dec 2007 Positive results have been reported by Amylin.